Overdiagnosed: Making the Case Against Finding Too Much

Overdiagnosed: Making People Sick in the Pursuit of Health was published by Beacon Press in 2011. Its authors, H. Gilbert Welch, Lisa Schwartz and Steven Woloshin, are physician-researchers who spent much of their careers studying the outcomes of medical testing, particularly cancer screening.

The book is not a memoir and has no single patient at its center. It is an argument, built case by case across several conditions, that modern medicine's drive to find disease earlier and more thoroughly has a real cost: it finds abnormalities that meet a technical definition of disease but would never have caused a symptom or shortened a life.

The authors distinguish this carefully from misdiagnosis. A misdiagnosis is wrong. An overdiagnosis is, by their definition, correct: a real cancer, correctly identified under a microscope, that simply would never have grown fast enough, or at all, to matter in that person's remaining lifetime. The problem is not the test's accuracy. It is what happens after an accurate test finds something biology was never going to act on.

The book's title captures its overall claim: that the pursuit of ever-earlier, ever-more-thorough detection can make healthy people into patients, with all the treatment burden that follows, without extending anyone's life.

The book is organized around a series of case studies drawn from different areas of medicine, cancer screening prominent among them. Chapters examine breast cancer screening, prostate cancer screening (through PSA testing), and thyroid cancer, alongside non-cancer examples such as high blood pressure and osteoporosis, to build a general argument that applies across specialties, not one confined to oncology.

Each case follows a similar structure: what the screening test finds, what fraction of what it finds would never have caused harm if left alone, and what happens to the people who are treated for a condition that was never going to become symptomatic disease. The prostate cancer chapter, drawing on PSA screening data available at the time, is one of the book's most detailed, because prostate cancer has long been recognized as having an unusually high rate of indolent, slow-growing disease detected by screening.

The book also lays out the statistical concepts underlying its argument in accessible terms: lead-time bias, in which early detection makes survival time look longer without changing when death occurs, and the difference between disease incidence, which testing can inflate, and disease mortality, the number that actually reflects whether more testing is saving lives.

There is a closing section addressing what more selective, evidence-based screening could look like, and how a patient might think about a screening decision differently once overdiagnosis is understood as a real, quantifiable harm rather than a hypothetical one.

The book's central conceptual contribution, that overdiagnosis is a real, distinct, and measurable harm rather than a semantic quibble, has held up and become part of how federal agencies themselves now describe screening tradeoffs, discussed below.

Its use of mortality data, rather than survival statistics alone, to evaluate whether more screening is actually saving lives is methodologically sound and reflects a real, ongoing debate within evidence-based medicine about how screening programs should be evaluated.

The authors write clearly and avoid dismissing the emotional weight of a cancer diagnosis even as they build a statistical case against overtesting; the book does not read as cold or dismissive of patients' fear, which is a real risk for books making this kind of argument.

The book is now more than fifteen years old, and screening guidance in several of the areas it discusses has changed materially since publication. USPSTF revised its breast cancer screening recommendation in 2024, moving to a straightforward biennial mammography recommendation from age 40, a change from the more individualized guidance for the 40-49 age range that existed when the book was written. Any specific screening age or interval described in the book should be treated as reflecting 2011 guidance, not current guidance.

The book's argument, taken in isolation and without its careful qualifications, can be misread as an argument against screening generally. That is not what the authors argue; their case is for more selective, evidence-based screening, calibrated to where evidence shows benefit outweighs harm, not for abandoning screening. A reader should be careful not to extend the book's specific critiques of certain tests, in certain populations, at certain intervals, into a blanket dismissal of screening as a category.

The book also predates much of the current debate about screening in specific higher-risk populations, including expanded genetic risk assessment, which can change the benefit-harm calculation for an individual in ways the book's population-level analysis does not fully capture.

This book is itself a useful model for evaluating claims about screening, cancer or otherwise, and it is worth naming its method explicitly.

A strong claim about a screening test, in the book's own framework, distinguishes between disease incidence and disease mortality, and states clearly what fraction of detected cases would have caused harm if left alone versus what fraction would not have. A weak claim treats "found early" as automatically equivalent to "lives saved," without that distinction.

A strong claim also names the population the evidence applies to, since the benefit-harm balance of a given screening test differs by age, risk factors and other individual circumstances; USPSTF's own grading system exists precisely to make those population-specific judgments explicit and current. A weak claim generalizes across age groups without acknowledging that the same test can carry a favorable balance in one age group and an unfavorable one in another.

Readers can apply this same test to the book's own claims: check whether a specific figure it cites still matches USPSTF's current recommendation, since the guidance in several areas the book covers has been revised since 2011.

USPSTF currently recommends biennial screening mammography for women aged 40 to 74, a Grade B recommendation, a straightforward age-based recommendation that replaced the previous individualized guidance for ages 40-49 the book was responding to.

For prostate cancer, USPSTF's current recommendation reflects the same overdiagnosis concern the book raises directly. For men aged 55 to 69, USPSTF assigns PSA-based screening a Grade C, meaning the decision should be individualized rather than offered as a blanket recommendation, because the modest potential benefit, roughly 1.3 prostate cancer deaths prevented per 1,000 men screened over 13 years by USPSTF's own estimate, comes with considerable potential harms including false positives, overdiagnosis, and treatment complications such as incontinence and erectile dysfunction. For men 70 and older, USPSTF recommends against PSA-based screening entirely, a Grade D.

NCI's own breast cancer screening page, current as of this writing, states the overdiagnosis concern in nearly the same terms the book uses: some cancers found during screening may not have caused problems during a woman's lifetime and would not have needed treatment, alongside false-positive results, which NCI says can cause emotional distress and require further procedures such as biopsies.

The convergence is notable. A book arguing against unchecked expansion of screening in 2011 and the federal guidance current in 2026 describe the same tradeoff, in similar language, even where the specific numbers have moved. For the fuller current picture, see cancer overdiagnosis, breast cancer screening, and false positive cancer screening results, which covers the anxiety and follow-up burden the book describes in more detail.

One measurable legacy of the book, and of the broader body of research its authors contributed to, is visible in how USPSTF itself now writes its recommendations. Current USPSTF recommendation statements routinely include an explicit discussion of "harms of screening" alongside benefits, quantify overdiagnosis and false-positive rates where evidence allows, and assign different grades to different age ranges specifically because the benefit-harm balance differs by age, exactly the kind of nuanced, quantified treatment the book argued medicine needed more of. This did not happen because of the book alone; it reflects a broader shift in evidence-based medicine methodology that the authors were part of, both in this book and in their separate academic research careers. But the convergence between the book's central methodological argument and how federal screening guidance is now actually written is real and checkable, and it is one reason the book has remained relevant well past its original publication date.

This book suits a reader who wants to understand why "more testing" is not automatically the same as "better care," and who is comfortable engaging with statistical reasoning presented in plain language. It is particularly useful for a reader facing a screening decision who wants to understand the concept of overdiagnosis before that conversation, not as a replacement for it.

It does not suit a reader looking for a current, up-to-date screening recommendation; several of the specific guidelines it references have since changed. It also does not suit a reader who wants the book to settle the individual question of whether they, personally, should be screened; that decision depends on individual risk factors current guidance is built to weigh, discussed with a clinician who has that individual's history.

Cancer Explained is free and ad-free, and you can support this work if it helped.

• Wikipedia — Overdiagnosed: Making People Sick in the Pursuit of Health
• USPSTF — Breast Cancer: Screening
• USPSTF — Prostate Cancer: Screening
• NCI — Screening for Breast Cancer

This page discusses Overdiagnosed for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care.